Tyra Biosciences, Inc. (TYRA)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Wall Street Analysts See a 178.82% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 178.8% in Tyra Biosciences (TYRA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
On Thursday, Tyra Biosciences, Inc. TYRA released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study.
Tyra Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 55 | $595.85 | $1,754.4 | $1,158.55 | 194.44% |
 Farallon Capital Farallon Capital Management LLC | 3.58M | $97.49M | $114.47M | $16.98M | 17.42% |
| BG Bart Gancher Intech Investment Management LLC | 6,345 | $60,715.44 | $202,024.8 | $141,309.36 | 232.74% |
 John H. Burbank III Passport Capital LLC | 10,607 | $146,907 | $337,726.88 | $190,819.88 | 129.89% |
 Point72 Asset Management LP Point72 Asset Management LP | 38,850 | $1.02M | $1.24M | $221,254.61 | 21.66% |
Tyra Biosciences, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GM Geoff Meacham B of A Securities | 1,401.35 | $18,371.29 | $45,375.56 | $27,004.27 | 146.99% |
Tyra Biosciences, Inc. (TYRA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tyra Biosciences, Inc. ever had a stock split?
Tyra Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Todd Harris CEO | NASDAQ (NGS) Exchange | 90240B106 CUSIP |
| US Country | 87 Employees | - Last Dividend | - Last Split | 15 Sep 2021 IPO Date |
Overview
Tyra Biosciences, Inc. is a preclinical-stage biopharmaceutical company focus on creating innovative therapies aimed at overcoming tumor resistance, thereby enhancing treatment outcomes for patients with cancer. Established in 2018, Tyra Biosciences is headquartered in Carlsbad, California. The company's research and development efforts are particularly centered on addressing the challenges posed by specific genetic mutations and resistance mechanisms in cancer cells, with an emphasis on utilizing precision medicine techniques to design and develop targeted therapies.
Products and Services
- TYRA-300
A leading product candidate from Tyra Biosciences, TYRA-300 is a selective inhibitor focusing on fibroblast growth factor receptor 3 (FGFR3), designed for the treatment of muscle invasive bladder cancer. This compound represents the company's strategic pursuit of targeted therapy options that can directly inhibit the growth and spread of cancer cells through specific genetic pathways.
- FGFR2-Targeted Program for Intrahepatic Cholangiocarcinoma
Under development to address intrahepatic cholangiocarcinoma, this program targets the fibroblast growth factor receptor 2 (FGFR2). By focusing on genetic abnormalities specific to this type of cancer, Tyra Biosciences aims to offer a targeted therapeutic option that can potentially improve treatment precision and efficacy.
- Program for FGFR3-Related Achondroplasia
Expanding its portfolio beyond oncology, Tyra Biosciences is also working on a program targeting FGFR3-related achondroplasia, a genetic condition affecting bone growth. This signifies the company's commitment to leveraging its expertise in FGFR pathways for broader therapeutic applications.
- RET Kinase Target Program
This program focuses on the development of treatments targeting the REarranged during Transfection (RET) kinase. By inhibiting the activity of this protein, Tyra Biosciences aims to offer therapeutic options for cancers that are driven by alterations in the RET gene, showcasing the company’s dedication to addressing a wide range of oncogenic drivers.
- FGFR4-Related Cancers Program
Targeting cancers related to abnormalities in the fibroblast growth factor receptor 4 (FGFR4), this program represents another dimension of Tyra Biosciences' approach to combat cancer through precision medicine. The focus here is on harnessing the potential of targeted therapy to inhibit cancer progression associated with FGFR4 mutations.
- SNAP Platform
The SNAP platform is Tyra Biosciences' proprietary technology designed to accelerate the structural design of targeted therapies. Through iterative molecular "SNAPshots", this platform enables the rapid and efficient development of drug compounds, thus facilitating the company's agile response to emerging therapeutic needs in oncology and beyond.
